Previously we have reported that deregulated expression of c-myc in normal and leukemic myeloid cells blocked dierentiation and, concomitantly, induced p53-independent apoptosis. Here, we show that this morbidity was due to premature recruitment of the Fas/CD95 cell death pathway which normally operates to induce apoptosis at the end of the terminal myeloid dierentiation program. Analysis of the regulated components of this pathway revealed that IL6-mediated induction of dierentiation resulted in rapid cell surface expression of CD95 receptor. Deregulated c-myc prevented the downregulation of CD95 ligand by maintaining its transcription, but caused premature downregulation of c-FLIP. First, the Type II (mitochondria-dependent, bcl-2-sensitive) and, then, the Type I (mitochondria-independent, bcl-2-insensitive) pathway were activated. Stable exogenous c-FLIP expression completely rescued the apoptotic phenotype. Furthermore, when the deregulated c-myc transgene was stably transduced into bone marrow cells from Fas lpr/lpr (CD95 receptor mutant) and FasL gld/gld (CD95 ligand mutant) mice, cell death was signi®cantly suppressed relative to c-myc-transduced wild type bone marrow cells upon induction of dierentiation. These data indicate that c-myc-mediated apoptosis associated with blocks in myeloid dierentiation is dependent on the Fas/CD95 pathway. Our ®ndings oer important new insights into understanding how deregulated c-myc alters normal blood cell homeostasis, and how additional mutations might promote leukemogenesis.
Introduction
The regulation of hematopoiesis is implemented, in large part, by a complex network of cytokines, feedback loops and the cellular microenvironment of organs where blood cell formation occurs. Like other hematopoietic cell lineages, the genesis of mature myeloid cells from precursors is a tightly regulated process that involves proliferation, growth arrest linked to terminal dierentiation, and, ultimately, programmed cell death (Metcalf, 1991) . Aberrations in these crucial processes can lead to disease states such as preleukemic myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), or acute myeloid leukemia (AML) (Sawyers et al., 1991) . AML, for example, results from a clonal expansion of myeloid cells that are blocked in their ability to dierentiate. A block in dierentiation can be caused by misregulated expression of a proto-oncogene such as c-myc (Homan-Liebermann and Liebermann, 1991a) . Indeed, overexpressed c-myc, in combination with deregulated Bcl-2, a suppressor of apoptosis, can eciently transform hematopoietic cells (Vaux et al., 1988) . c-myc has been shown to play a pivotal role in the control of proliferation, dierentiation and apoptosis, and its deregulated expression participates in the progression of a wide range of neoplasias (Eilers, 1999; Facchini and Penn, 1998; Nesbit et al., 1999; Schmidt, 1999; Spencer and Groudine, 1991) . Repression of c-myc is required for terminal dierentiation of many cell types, including myeloid cells (Freytag, 1988; Homan-Liebermann and Liebermann, 1991b; Packham and Cleveland, 1995) . We have recently shown that the deregulated expression of c-myc in both M1 myeloid leukemic cells and normal myeloid cells derived from murine bone marrow (BM) not only blocked terminal dierentiation and its associated growth arrest, but also induced a p53-independent apoptotic pathway (Amanullah et al., 2000) . The apoptotic response was not completely penetrant; both proliferation and apoptosis were continuously ongoing in the same population of cells.
The CD95/Fas death receptor is probably the best characterized member of the tumor necrosis factor (TNF) family of receptors (Nagata, 1997) . Engagement of the CD95 receptor by its cognate ligand, CD95L, results in the recruitment of an adapter molecule, FADD, to the cytoplasmic domain of the receptor (Boldin et al., 1995; Chinnaiyan et al., 1995) . This is followed by the binding of procaspase-8 to FADD and auto-processing of the inactive procaspase-8 to the active caspase-8 moiety (Boldin et al., 1996; Muzio et al., 1996) . Caspase-8 is an apical caspase whose activation in turn leads to a cascade of catalytic activation of eector caspases, such as caspase-3, that culminates in apoptosis (Nunez et al., 1998) . The CD95/Fas pathway can be shut o by an intracellular inhibitor, c-FLIP, which competes with procaspase-8 for binding to FADD (Irmler et al., 1997) .
In this work, we have studied the molecular mechanisms that are involved in c-myc-mediated apoptosis associated with blocks in myeloid dierentiation. We present evidence that the cell death following normal myeloid terminal dierentiation utilizes the CD95/Fas apoptotic pathway and that deregulated cmyc, in conjunction with blocking the progression of terminal dierentiation, prematurely triggers this same death receptor pathway.
Results

Activation of caspase-8 and effect of agonistic anti-CD95 antibody
We have previously shown that the deregulated expression of c-myc in myeloid cells not only blocks terminal dierentiation, but also induces a concomitant program of p53-independent apoptosis (Amanullah et al., 2000) . Since little is known about the molecular controls underlying c-myc-mediated apoptosis associated with blocks in dierentiation, the mechanistic basis for the observed cell death was investigated. As an initial approach, we examined whether this was a caspasedependent or independent process. It was found that among the caspases that were activated was a member of the`executioner' class, caspase-3 (data not shown), and an`initiator' caspase, caspase-8 ( Figure 1a ). This caspase was induced at an early time point (day 1) in IL6-treated M1myc and signi®cantly later (day 4) in parental M1 cells, consistent with the observed apoptosis associated with the end of the terminal dierentiation program in the latter cell line. Since the kinetics of induction of caspase-8 activity correlated very well with the kinetics of apoptotic cell death (Figure 1b) , we tested the hypothesis that a cell death pathway that utilized caspase-8 was central to the dierentiation-associated apoptosis in myeloid cells. One such pathway is the TNFR1 pathway and another is the well characterized CD95/Fas pathway (Nagata, 1997) . To see if either the TNFR1 or CD95/Fas death receptor was involved, recombinant TNF-a or agonistic anti-CD95 antibody, respectively, was added to IL6-treated M1 and M1myc cells. While the addition of TNF-a did not enhance the cell death response of either IL6-treated M1 or M1myc cells (data not shown), agonistic anti-CD95 antibody dramatically accelerated the cell death of IL6-treated M1myc cells (Figure 1c ). The apoptotic cell death normally associated with the end of terminal dierentiation of M1 cells was only slightly augmented by agonistic anti-CD95 antibody treatment. This observation is consistent with either the death rate of these cells already being near maximal at late time points or, alternatively, the involvement of another cell death mechanism. Addition of anti-CD95 antibody to control M1 and M1myc cells, that were not treated with IL6, had no detectable eect on cell survival or growth (data not shown).
Regulation of CD95 receptor, CD95L, FADD and c-FLIP
The preceding results suggested that the CD95/Fas death receptor pathway may indeed be a critical component of the c-myc-mediated cell death. Consequently, the possible regulation of the major components of this pathway (Figure 2a ) during apoptosis was studied. FACS analysis was used to examine the cell surface expression of the CD95 receptor. Figure 2b shows that IL6 induced expression of receptor equally in both M1 and M1myc cells. Furthermore, the CD95 receptor was rapidly expressed in both cell lines, appearing as early as 2 h post-treatment and reaching maximum levels at about 40 h (Figure 2c ).
RT ± PCR and Western blot analyses indicated that FADD, the adapter molecule, was constitutively expressed in both M1 and M1myc cells, and these levels were not aected by IL6 (Figure 3a) . However, at early time points (i.e. up to day 3), co-immunoprecipitation of FADD with the CD95 receptor, indicative of the formation of a functional CD95 receptor-CD95 ligand complex and subsequent recruitment of FADD, was only observed in IL6-treated M1myc and not in similarly treated M1 cells (Figure 3b ). Consistent with this observation, CD95 ligand (CD95L), which is constitutively expressed in untreated M1 and M1myc cells, was downregulated in IL6-treated M1 cells, but was maintained in IL6-treated M1myc cells (Figure 3c ).
To understand how c-myc might regulate CD95L levels, we took advantage of a M1mycER cell line (Selvakumaran et al., 1993) . In this cell line the MYC activity of the mycER fusion protein is dependent on exogenous B-estradiol, whereas the endogenous c-myc gene is under normal cellular control. Figure 3d shows that, as with the parental M1 cells, in M1mycER cells CD95L mRNA was downregulated in response to IL6 and was undetectable by 34 h post-treatment. Addition of B-estradiol at this point resulted in the reappearance of CD95L mRNA. Moreover, the simultaneous addition of the protein synthesis inhibitor, cycloheximide, together with B-estradiol to IL6-treated M1-mycER cells did not inhibit the induction of CD95L transcripts. This shows that the CD95L gene can be transcriptionally regulated by c-myc, consistent with the observations of Kasibhatla et al. (2000) .
The CD95/Fas pathway is negatively regulated by the cellular inhibitor c-FLIP (Figure 2a c-myc-mediated apoptosis activates both Types I and II CD95/Fas pathways Ligation of the CD95 receptor can induce at least two apoptotic pathways (Scadi et al., 1998) . The Type I pathway results in relatively high levels of caspase-8 which then directly activates downstream eector /ml in the presence of IL-6 (50 ng/ml) and, at the indicated times, were lysed. The lysates were then either assayed for IETD-ase activity, as described in Materials and methods or were subjected to Western blot analysis. The IETD-ase assay was repeated four times and each time point is the average with standard deviation shown. (b) Analysis of genomic DNA from M1 and M1myc cells stimulated with IL-6. Genomic DNA was extracted from 1610 7 cells at the indicated time points, end-labeled, and resolved on an agarose gel (500 ng/lane). This experiment was repeated three times with similar results. (c) Eect of agonistic anti-CD95 antibody (clone Jo2; Pharmingen, CA, USA) on M1 and M1myc cells treated with IL6. Cells were seeded at 0.15610 6 /ml in the presence or absence of anti-CD95 antibody (200 ng/ml). IL6 was added immediately and the number of viable cells was determined at the indicated time points by Trypan blue dye exclusion and counting in a hemocytometer. Each time point is the average of three experiments, with a standard deviation of up to 15%. Addition of anti-CD95 antibody to control M1 and M1myc cells that were untreated with IL6 had no detectable eect on cell survival or growth (data not shown) caspases, such as caspase-3. It is not dependent on mitochondrial function and is, therefore, insensitive to modulation by members of the Bcl-2 family. The Type II pathway is responsive to even low caspase-8 levels, which are sucient to cleave Bid, the pro-apoptotic Bcl-2 family member (Li et al., 1998 and Figure 2a) . Truncated Bid translocates to mitochondrial membranes, where it is thought to eect selective mitochondrial membrane depolarization and release of cytochrome c. These events lead to the eventual activation of caspase-9 and, ®nally, cell demise via induction of eector caspases (Susin et al., 1997) . Due to its dependence on membrane depolarization of mitochondria, the Type II pathway can be inhibited by anti-apoptotic Bcl-2 family members .
We have previously reported that overexpression of Bcl-2 could delay, but not completely suppress, the cmyc-mediated apoptosis in IL6-treated M1myc/Bcl-2 cells (Amanullah et al., 2000) . Because of the sensitivity of the Type II CD95/Fas pathway to anti-apoptotic members of the Bcl-2 family, we investigated whether this pathway was part of the apoptotic response in M1myc cells. Figure 5a shows that in M1myc cells, cytochrome c was released to the cytosolic fraction as early as one day after addition of IL6. In M1 cells, cytochrome c was not detected in the cytosol until day 5 following treatment with IL6. In both bases, the appearance of cytochrome c in the cytosolic fraction correlated with the onset of apoptosis. In contrast, overexpressed Bcl-2 completely prevented cytochrome c release even as late as 7 days in M1myc/Bcl-2 cells. (10 6 ) were collected during the indicated time course and stained with anti-CD95 antibody (1 mg) and FITC-conjugated secondary antibody (0.5 mg). The cells were then subjected to FACS analysis as described in Materials and methods. This experiment was repeated three times. Each time point in (b) is the average of three experiments, with a standard deviation of up to 15% However, despite this suppression, the onset of cell death was not prevented, but only delayed ( Figure 5b ). These data revealed a biphasic CD95/Fas apoptotic program in IL6-treated M1myc cells. At early time points (until day 4), Bcl-2 was able to inhibit cell death, indicative of the Type II pathway, whereas at later time points Bcl-2 had no eect on cell survival, indicative of the Type I pathway. Exogenous expression of Bcl-2 in IL6-treated parental M1 cells, on the other hand, did not signi®cantly delay the cell death associated with the end of the terminal dierentiation program (data not shown). This observation is consistent with the very high levels of caspase-8 induced in these cells, which allows a functional bypass of the Type II pathway and suggests that apoptosis is mediated almost completely by the Type I (Bcl-2-insensitive) pathway.
c-myc-mediated apoptosis of bone marrow cells from lpr and gld mice is suppressed Our previous work had shown that deregulated expression of c-myc also blocked terminal dierentiation and induced apoptosis in myeloid cells derived from BM (Amanullah et al., 2000 and Figure 6 ). The availability of Fas lpr/lpr (CD95 receptor-mutant) and FasL gld/gld (CD95L-mutant) mutant mice allowed us to assess the relative contribution of the CD95/Fas pathway to this apoptotic response. It is formally possible that in addition to the CD95/Fas pathway, other TNF death receptor pathways, such as DcR1, DcR2, DR4 and DR5 (reviewed in Ashkenazi and Dixit, 1998) or even as yet uncharacterized pathways that activate caspase-8 are also involved.
BM cells from Fas lpr/lpr and FasL gld/gld mice were stably transfected with c-myc and induced for dierentiation with IL3 or GM-CSF. As with normal BM cells, c-myc blocked the dierentiation of Fas lpr/lpr and FasL gld/gld BM cells ( Figure 6 ). However, apoptosis was highly suppressed in both cases relative to the wild type control. These experiments demonstrate that c-mycmediated apoptosis associated with blocks in dierentiation almost exclusively engages the CD95/Fas pathway.
The role of CD95/Fas in normal myeloid differentiation
We addressed the issue of whether the apoptotic cell death associated with the end of terminal myeloid dierentiation also utilized the CD95/Fas pathway. This possibility was initially suggested to us by the early rapid induction of the CD95 receptor ( Figure  2b ,c) and consequent caspase-8 activity at later times (by day 4) following induction of M1 terminal dierentiation (Figure 1a) . Although CD95L was downregulated at early time points, it was upregulated at late time points (Figure 7a ). Expression of c-FLIP was unaected by IL6 until day 5, at which point it was downregulated (Figure 7b ). Both the upregulation of CD95L and downregulation of c-FLIP were coincident with the onset of apoptosis. As was the case with M1myc/FLIP cells, the deregulated overexpression of c-FLIP in M1 cells suppressed apoptotic cell death (Figure 7c ). On average, IL6-treated M1/ FLIP clones survived 4 to 5 days longer than similarly treated M1 cells (data not shown). Furthermore, the eventual death of the M1/FLIP cells was necrotic and not apoptotic, as indicated by morphology (not shown) Figure 3 Regulation of FADD and CD95L in IL6-treated M1 and M1myc cells. (a) For RT ± PCR analysis of FADD mRNA expression, cells were harvested at the indicated times, mRNA was extracted, reverse transcribed and PCR was carried out using primers speci®c for FADD and actin. The products were resolved on a 2% agarose gel. Three hundred mg per sample of total protein extract were fractionated on a 15% SDS ± PAGE gel for FADD protein expression analysis and the resulting Western blot was probed with an anti-mouse FADD antibody (Santa Cruz Biotech, CA, USA). (b) Activation-dependent recruitment of FADD to the CD95 receptor in IL6-treated M1myc cells. Four hundred mg of protein lysate from each indicated time point was incubated with 20 mg of anti-CD95 antibody and immunoprecipitated (Materials and methods). Co-immunoprecipitated proteins were resolved on a 15% SDS ± PAGE gel and subjected to Western blot analysis using the anti-mouse FADD antibody. (c) RT ± PCR and Western blot analyses of CD95L expression were carried out as described in (a) except that primers and antibody speci®c for murine CD95L were used. (d) c-myc induced CD95L expression in the absence of de novo protein synthesis. M1mycER cells were treated with IL6 (50 ng/ml) for the indicated time periods and CD95L expression was determined by RT ± PCR. Following IL6-treatment for 34 h to allow complete endogenous c-myc downregulation, the mycER transgene was activated (+beta-estradiol at 2 mM) with or without cycloheximide (10 mg/ ml) for an additional 3 h. All of the above experiments were repeated at least three times; representative experiments are shown and absence of genomic DNA ladders (Figure 7c ). These ®ndings are consistent with terminally dierentiating M1 cells undergoing apoptosis via the CD95/ Fas pathway. This point will be further addressed in the next section.
Discussion
The principal aim of this investigation was to elucidate the molecular mechanisms that underlie c-mycmediated apoptosis associated with blocks in dierentiation. Our results suggest that both the Types I and II CD95/Fas death receptor pathways are prematurely activated in myeloid cells that constitutively express cmyc in conjunction with blocking dierentiation.
Although previous studies had implicated a role for CD95/Fas in the c-myc-induced apoptosis of rodent ®broblasts (Hueber et al., 1997; Kagaya et al., 1997) , it was not exactly clear how c-myc interfaced with this pathway. Recently, it had been suggested that in rodent ®broblasts there was constitutive, low level autocrine CD95-CD95L interaction; c-myc triggered cell death by inducing the release of mitochondrial cytochrome c, which then served to lower the threshold for CD95/Fas signaling (Juin et al., 1999) . Our data are, in part, consistent with the interpretation that cytochrome c release is involved; however it is not necessary.
We showed that there was a biphasic activation of CD95/Fas signaling. Initially, the Type II pathway was induced, and at later time points a switch to the Type I mode was observed. This was an intriguing result since most reports to date have implicated either one or the other CD95/Fas signaling subpathways, depending on cell type, but not both simultaneously in the same cell type (Scadi et al., 1998) . Interestingly, while hepatocytes from Bid-de®cient mice were resistant to CD95-mediated apoptosis, thymocytes from the same animals were not as dependent on Bid, and exhibited 7 cells were collected and lysed. After pelleting of unlysed cells and nuclei, the mitochondrial fraction (M) and cytosolic supernatant fraction (S) were separated by centrifugation at 13 000 g. For Western blot analysis, 10 mg of the mitochondrial and 20 mg of the supernatant fraction were resolved on a 15% SDS ± PAGE gel and an anticytochrome c antibody (murine; Pharmingen, CA, USA) was used to detect cytochrome c. (b) Apoptosis of IL6-treated M1myc cells is delayed by exogenous Bcl-2 expression. Genomic DNA was extracted from 1610 7 cells at indicated times post-treatment with IL6, end-labeled, and resolved on an agarose gel. These experiments were performed at least three times and representative results are shown ) bone marrow (BM) cells were infected with either MSCVneo or MSCVmyc/neo, as described in Materials and methods. Cells were seeded in methyl cellulose with IL-3 (10%) and G418 (400 mg/ml). After 7 days colonies were picked and transferred to liquid culture in the presence of G418 and either IL-3 (10%) or GM-CSF (100 ng/ml). After 5 days, cells in liquid culture were analysed for per cent dierentiated cells and presence of DNA ladders. This experiment was repeated three times with similar results. The data shown is a representative experiment Figure 7 Deregulated expression of c-FLIP suppresses the apoptosis associated with normal terminal myeloid dierentiation. Regulation of (a) CD95L and (b) c-FLIP in the apoptosis associated with terminal dierentiation of M1 cells. RT ± PCR and protein expression analyses were performed as described in Figure 3a . (c) Deregulated expression of c-FLIP in IL6-treated M1FLIP cells suppresses apoptotic cell death (note absence of DNA ladders at day 11 time point) associated with terminal dierentiation. Genomic DNA was extracted and analysed as previously described in Figure 1b . This experiment was repeated with four independent M1FLIP clones and similar results were obtained only a delay in CD95-mediated apoptosis (Yin et al., 1999) . This is reminiscent of the delay observed in IL6-treated M1myc/Bcl-2 cells. Additionally, it was demonstrated that Bcl-2 could only partially block CD95-mediated death in myelomonocytic progenitors since only half the Bcl-2-expressing BM cells from CD95 +/+ mice survived in vivo activation of the CD95/Fas pathway (Traver et al., 1998) .
Unlike the studies with rodent ®broblasts (Hueber et al., 1997; Juin et al., 1999) , our results with myeloid cells also support a more direct role for c-myc in the recruitment of the CD95/Fas pathway. While IL6 rapidly induced cell surface CD95 receptor expression in M1myc cells (Figure 2 ), c-myc prevented the downregulation of CD95L (Figure 3c) . Furthermore, our data shows that c-myc is a transcriptional regulator of CD95L. This role for c-myc is consistent with other studies that have suggested that c-myc is required for the regulation of CD95 ligand expression in the process of activation-induced cell death in T-cells Genestier et al., 1999) . The CD95L promoter contains a non-canonical (ATTCTCT) binding site for c-myc . When the canonical cmyc-responsive element (CACGTG) of the ornithine decarboxylase (a myc target gene) promoter was replaced by the non-canonical element, the modi®ed promoter was even more responsive to c-myc. A similar or identical non-canonical myc-responsive sequence has also been identi®ed in the promoters of other genes such as HSP70 (Taira et al., 1994) , c-myc itself (Ariga et al., 1989) , and in the EFII enhancer of the Rous sarcoma virus LTR (Hann et al., 1994) . Interestingly, the physiological importance of this myc-responsive element is further supported by the observations that the non-canonical sequence exhibits binding to in vivoderived Myc protein (Hann et al., 1994) and it eciently binds to Myc ± Max heterodimers, but not to either Myc or Max homodimers (Hann et al., 1994; Kasibhatla et al., 2000) .
Our results demonstrated additional consequences of deregulated c-myc expression with regard to modulating CD95/Fas mediated apoptosis. In combination with IL6, c-myc suppressed the transcription of c-FLIP, an inhibitor of the CD95/Fas pathway ( Figure  4a ). We have previously reported that the cell death induced by deregulated c-myc in IL-6-treated M1myc cells was not completely penetrant; it was a stochastic process in which the cells that survived continued to proliferate until some proportion of them succumbed to apoptosis (Amanullah et al., 2000) . That c-FLIP was not completely absent (Figure 4a ) probably accounts for this; c-FLIP was absent from or below threshold levels in cells that were undergoing cell death and present above threshold levels in the surviving cell population. The addition of agonistic anti-CD95 antibody may have raised the threshold level of c-FLIP required to protect the cells, resulting in enhanced apoptosis. Several attempts to directly correlate the absence of c-FLIP with the apoptotic cells, using both immunohistological and doublestaining FACS analysis, have so far been unsuccessful because of the lack of a suitable anti-murine c-FLIP antibody. Additionally, the mechanism by which c-myc (in collaboration with IL6) downregulates c-FLIP is not clear at present, and will require further investigation. Nonetheless, the critical nature of the c-FLIP downregulation in the apoptotic response was demonstrated by stably expressing c-FLIP in M1myc cells. Exogenous c-FLIP restored the normal growth kinetics of M1myc cells and completely rescued the apoptotic phenotype (Figure 4b,c) .
Our previous work had indicated that while IL6-treated M1myc cells entered into an early apoptotic program, the parental M1 cells also underwent apoptotic cell death, but only at the end of the normal dierentiation process (5 ± 7 days post-treatment with IL6; ref 1). IL6 induced cell surface CD95 receptor expression in M1 cells with the same rapid kinetics as in M1myc cells (Figure 2c ) and high levels of caspase-8 activity were detectable coincident with the onset of loss of viability of M1 cells (Figure 1a,b) . Further examination revealed that even though CD95L message was downregulated in response to IL6 by day 2, it was induced again at day 4 (Figure 7a ). In agreement with the notion that c-myc can positively upregulate CD95L in this cell system, the initial decrease in CD95L transcripts parallels the IL6-induced downregulation of c-myc (Homan-Liebermann and Liebermann, 1991b) . The promoter of the CD95L gene contains an AP-1 regulatory element among other control sequences (Harwood et al., 2000) . Since IL6 turns on the expression of components of the AP-1 transcription factor complex, such as JunB and c-fos, as part of the dierentiation response of myeloid cells (Liebermann and Homan, 1994) , CD95L expression may be reactivated via the AP-1 site at the late time points. This will need to be tested experimentally.
The control of c-FLIP expression is probably an important regulatory node in other caspase-8-mediated apoptotic responses of the hematopoietic system. For example, c-FLIP has been demonstrated to be downregulated in activated T-cells in response to another key cytokine, IL2 (Refaeli et al., 1998) . Similarly, c-FLIP is downregulated when apoptosis of IL-6-treated M1 cells is initiated (Figure 7b ). As with M1myc cells, the importance of this downregulation was indicated by the response of M1/ FLIP cells to IL6. IL6-treated M1/FLIP cells underwent normal dierentiation, but the suppression of apoptosis extended their viability. When these cells did succumb, they did so by a necrotic mode and not by apoptosis, as determined by cell morphology (not shown) and the absence of genomic DNA ladders (Figure 7c ). These ®ndings are consistent with terminally dierentiating M1 cells undergoing apoptosis via the CD95/Fas pathway. The observations of Fecho et al. (1998) with bone marrow cells from CD95-mutant and CD95L-mutant mice indicate that the absence of CD95 or CD95L has only minor consequences for granulopoiesis. However, it is interesting to note that constitutive expression of the apoptotic suppressor Bcl-2 in myeloid cells of CD95-mutant Fas lpr/lpr mice often leads to a fatal disease analogous to human acute myeloblastic leukemia (Traver et al., 1998) . This demonstrates that, while not overt, the myeloid compartment in CD95-mutant mice is clearly compromised. Bcl-2 expression unmasks the critical importance of the CD95/Fas pathway in normal myeloid homeostasis.
The results presented in this study point to a central role for both the Type I and Type II CD95/Fas pathways in the c-myc-mediated apoptosis associated with blocks in dierentiation of myeloid cells. Cell death is initiated by an activation of the Bcl-2-sensitive Type II pathway. It has recently been shown that c-myc can suppress anti-apoptotic Bcl-2 family members (Eischen et al., 2001) , which suggests additional subtleties in the eect of c-myc on apoptosis. Suppression of Bcl-2 or Bcl-X L by c-myc may further potentiate the Type II CD95/Fas apoptotic pathway. Our data also indicate that the CD95/Fas death receptor pathway is an integral part of the apoptotic response associated with the end of the normal terminal dierentiation program and that deregulated c-myc expression can activate this signaling pathway prematurely. It appears, then, that in myeloid cells, the CD95/Fas apoptotic pathway might function in at least two ways to maintain homeostatic cell numbers. First, it contributes to the elimination of dierentiated myeloid cells at the end of their useful lifespan, and second, CD95/Fas may sensitize dierentiating cells to the presence of inappropriately expressed positive regulators of proliferation, such as c-myc and thereby facilitate the destruction of these cells. If unchecked, such aberrant cells could, by acquiring additional mutations, progress to a leukemic phenotype. Thus, these proposed functions are consistent with a role for CD95/Fas as a tumor suppressor.
Materials and methods
Cells, cell culture and cytokines
M1 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM; Gibco ± BRL, Gaithersburg, MD, USA) supplemented with 10% heat inactivated horse serum (Gibco ± BRL), and 1% penicillin and streptomycin (Gibco ± BRL). The M1myc cell line (Homan-Liebermann and Liebermann, 1991a) was similarly cultured, except that the culture medium was supplemented with 400 ng/ml G418 (Gibco ± BRL) in order to maintain selection of the transgene. The control M1neo cell line has been described previously (Homan-Liebermann and Liebermann, 1991a) ; it behaved similarly to parental M1 cells. Five independent M1myc clones responded in the same way to IL-6. Most of the biochemical analyses was done with one clone. M1mycER cells (Selvakumaran et al., 1993) were maintained in phenol red-free DMEM (Gibco ± BRL) and 10% dialysed horse serum. All cells were cultured in a humidi®ed atmosphere with 10% CO 2 at 378C. Cells were induced for dierentiation with IL-6 at 50 ng/ml (a generous gift from Amgen Inc., Thousand Oaks, CA, USA) after being seeded at a concentration of 0.15610 6 cells/ml.
Bone marrow infection, selection and expansion
Myeloblast enriched bone marrow (BM) cells, obtained from femurs of sodium caseinate injected, 3 ± 5-week-old mice (C57BL/6J wild type), B6.MRL-Fas lpr/lpr (CD95 receptor mutant), and B6Smn.C3H-FasL gld/gld mice (CD95 ligand mutant) from Jackson Laboratory, Bar Harbor, ME, USA), consist primarily of cells of the myeloid lineage (95+4%), with 33+3% myeloid precursors at the myeloblast to promyelocyte stage (Liebermann and Homan-Liebermann, 1989) . MSCV retroviral vectors, packaged as helper-free infectious ecotropic retroviruses using Bosc23 packaging cells (Pear et al., 1993) , were particularly ecient in infecting myeloblast enriched BM cells. Brie¯y, 10 mg of pMSCVneo and pMSCVmye/neo were transfected into Bosc23 cells using the calcium phosphate-DNA precipitation method (Pellicer et al., 1978) and after 48 h the cells were treated with mitomycin c (10 mg/ml) for 3 h. After repeated washings the cells were refed and BM was added (5610 6 cells) in the presence of polybrene (8 mg/ml), 10% interleukin-3 (IL-3) and recombinant rat stem cell factor (SCF, 200 ng/ml; a generous gift from Amgen Inc., Thousand Oaks, CA, USA). The source of IL-3 was WEHI-3B conditioned medium (Ymer et al., 1985) . The BM was cocultivated for 48 ± 72 h and then seeded in methylcellulose (StemCell Technologies, Inc.) with IL-3, and with or without G418 (650 mg/ml). After 7 days, colonies were assessed, both for number and morphology (compact, diuse). Cells from colonies were transferred to liquid culture for further analysis, in the presence of either IL-3 (10%) or murine recombinant GM-CSF (100 ng/ml; a generous gift from Amgen Inc., Thousand Oaks, CA, USA). Animal care and experimentation complied with all guidelines set forth by the National Institutes of Health and Temple University.
RNA extraction and RT ± PCR
Five 610 6 cells per sample were collected at the indicated time points and frozen at 7808C. Total RNA was extracted using TRIzol reagent (Gibco ± BRL) as described in the manufacturer's speci®cations. RNA was prepared from all samples at the same time in each experiment and quantitated. Ten mg of total RNA from each sample was reverse transcribed using the SuperScript TM II reverse transcriptase kit (Gibco ± BRL) according to the recommended manufacturer's protocol. Ten per cent of the resulting cDNA from each sample was subjected to 40 cycles of PCR consisting of 1 min at 948C, 1 min at 588C and 2 min at 728C in a 50 ml reaction mixture with 4 mM MgCl 2 , 0.4 nM dNTPs, 2 ml of each primer (10 ng/ml), 0.5 ml of Taq-DNA polymerase (5 U/ ml), and 5 ml of 106PCR buer (Gibco ± BRL). The PCR primers for murine FADD were 5'-ATGCTGAGAAGAA-GAACGCC-3' and 5'-GGTGACACAAGTTATCTCCAGG-3', for murine CD95-L, 5'-GCAGTGCCACTTCATCTTGG-3' and 5'-TGGTTGTTGCAAGACTGACC-3', for murine FLIP, 5'-TGAAGAGACTTACAGGATGCAGAGCAAGC-3' and 5'-TCTCCTTCACCGAAGCCACTGCAC-3' and for murine beta-actin, 5'-GAGCAAGAGAGGTATCCTGACC-3' and 5'-AGTAACAGTCCGCCTAGAAGC-3'.
Immunoprecipitations and Western blots
For the caspase-8 immunoprecipitation and Fas-FADD coimmunoprecipitation experiments, 4610 7 cells were lysed in 1 ml of lysis buer (50 mM Tris-Cl pH 7.4, 5 mM EDTA, 250 mM NaCl, 50 mM NaF, 0.1% Triton X-100, 0.1 mM sodium vanadate) supplemented with the protease inhibitors 1 mM PMSF and 10 mg/ml leupeptin. Clari®ed supernatants were collected and the protein concentration was determined using the micro-BCA protein quantitation kit (Pierce, Rockford, IL, USA). Four hundred mg of total protein was incubated with 20 mg of the appropriate antibody (anticaspase-8 was from Santa Cruz Biotech Inc., Santa Cruz, CA, USA, cat # 278 and anti-CD95 was from Pharmingen, San Diego, CA, USA, cat # 24586A) for 2 h at 48C. Thirty ml of Protein A-Sepharose (Pierce, Rockford, IL, USA, cat # 20334) was added to each sample and incubated at 48C for 1 h. After centrifugation, the samples were washed extensively in lysis buer. Preparation of protein extracts and subsequent Western blot analysis were carried out using standard techniques. Three hundred mg of each protein extract sample was fractionated on SDS ± PAGE gels and equal loading of protein was veri®ed by staining the blots with 0.1% Ponceau S solution (Sigma) prior to incubation with antibody. Signals were developed by using the enhanced chemiluminescence (ECL) Western blotting system (Amersham). Primary antibodies against CD95L and cytochrome c and the FITC-conjugated secondary antibody against hamster IgG were obtained from Pharmingen, San Diego, CA, USA (cat # 56734A, 23317A and 45896A respectively). The antibody against murine c-FLIP was from Upstate Biotechnology Inc. (cat # 8492) and anti-FADD was obtained from Santa Cruz Biotech Inc.
Assay of caspase-8 (IETD-ase) activity
Caspase-8 (IETD-ase) activity was assayed using the ApoAlert TM Flice/Caspase-8¯uorescent assay kit (Clontech, Palo Alto, CA, USA; cat # K2028-1) according to the manufacturer's recommended protocol. Brie¯y, 10 6 cells per sample were lysed and the supernatant collected. The IETD-AFC substrate (50 mM) was added together with reaction buer and the samples were incubated at 378C for 1 h. Fluorescent emission of the AFC product was detected with ā uorometer equipped with a 400 nm excitation ®lter and a 505 nm emission ®lter. To con®rm the speci®city of the protease reaction, control samples were preincubated with IETD-fmk inhibitor prior to the addition of IETD-AFC substrate. The amount of substrate cleaved as a function of time was determined using a standard calibration curve relative to free AFC as per the manufacturer's instructions (Clontech).
Establishment of M1myc/FLIP cell lines
The retroviral plasmid expression vector, MSCV-puromycin (puro), was a gift from Dr Robert G Hawley; University of Toronto, Toronto, Canada. To construct the MSCV-puro-FLIP vector, full-length murine c-FLIP (long) was cloned into the EcoRI site of the 6.3 Kb MSCV-puromycin plasmid. The 2.4 Kb c-FLIP fragment was excised from the pBS-FLIP vector (a kind gift of J Tschopp, University of Lausanne, Switzerland; Irmler et al., 1997) . Virus was generated from the plasmid forms of the retroviral vectors, MSCV-puro and MSCV-puro-FLIP by transient transfection (48 h) of the packaging cell line PA317 using calcium phosphate-DNA precipitation (Pellicer et al., 1978) . The resulting viral conditioned medium (VCM) was used to infect M1 and M1myc cells as previously described (Amanullah et al., 2000) .
For puromycin resistant colony selection, infected cells were seeded at 100 cells/ml in growth medium (DMEM+10% horse serum) containing puromycin at 4 mg/ml. At least ®ve independent clones expressing the c-FLIP transgene were examined for their response to IL-6. For each engineered cell line, all the clones behaved similarly. Control cell lines (M1/ MSCV-puro and M1myc/MSCV-puro clones) were indistinguishable from that of their respective parental cells.
Autoradiographic analysis of apoptotic DNA fragmentation
Genomic DNA was end-labeled by the method of Tilly and Hsueh (1993) which allows for the sensitive and quantitative detection of apoptotic DNA fragments. To facilitate the 3' end-labeling of apoptotically fragmented DNA, 500 ng of genomic DNA were incubated with 25 units of terminal deoxynucleotidyl transferase enzyme (Boehringer-Mannheim, BMB) and 50 mCi of radiolabeled dideoxy-nucleotide, [a 32 P]ddATP (3000 Ci/mmol; Amersham, Arlington Heights, IL, USA) in the presence of reaction buer (0.2 M potassium cacodylate, 2.5 mM cobalt chloride, 25 mM Tris-HCl, 1.25 mg/ml bovine serum albumin; pH 6.6) for 60 min at 378C. After removal of unincorporated radionucleotide by ethanol precipitation, the labeled DNA was resuspended in TE buer and subjected to electrophoretic analysis in a 2% agarose gel. Finally, the dried gel was exposed to Kodak XOmat ®lm for 30 min or more at 7808C.
Flow cytometric analysis
Two610
7 cells per sample were harvested by centrifugation, stained with anti-CD95 antibody (Pharmingen) on ice for 30 min. After washing twice, the cells were incubated with FITC-conjugated anti-hamster antibody (Pharmingen) on ice for 20 min, washed twice and subjected to analysis using a Coulter Epics Elite system (Miami, FL, USA).
Subcellular fractionation
Analysis of mitochondrial cytochrome release was carried out essentially as described by Juin et al. (1999) . Two610 7 cells were harvested at the indicated time points and resuspended in extraction buer (300 mm sucrose, 10 mm HEPES at pH 7.4, 50 mm KCI, 5 mm EGTA, 5 mm MgCl, 1 mm DTT, 10 mM cytochalasin B, 1 mm PMSF). After a 30 min incubation on ice, the cells were homogenized and cellular debris was removed by centrifugation for 10 min at 2000 g. The remaining supernatant was subjected to centrifugation at 13 000 g for 10 min to collect the mitochondrial fraction. The mitochondrial pellet was resuspended in extraction buer and together with the postmitochondrial supernatant, was frozen in liquid nitrogen and kept at 7808C. Comparable amounts of protein from the mitochondrial fractions (10 mg) and from the postmitochondrial supernatant fractions (20 mg) were fractionated by SDS ± PAGE and subjected to Western blot analysis.
